Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

A phase III randomized trial published in the New England Journal of Medicine found that two years of lenalidomide maintenance therapy provides equivalent overall survival to indefinite treatment for standard-risk multiple myeloma patients. The study of 516 patients showed 68.6% vs 69.0% survival rates at seven years, with indefinite treatment associated with higher toxicity and second primary cancer incidence. Results suggest fixed-duration maintenance could become the new standard of care.